Sandoz secures rights for Kerydin

PRINCETON, N.J. — Sandoz on Monday announced an agreement with Anacor Pharmaceuticals to obtain exclusive rights to commercialize Kerydin (tavaborole) topical solution, 5%, through its branded dermatology business, PharmaDerm. Kerydin is an antifungal approved for the treatment of onychomycosis of the toenails.



“Kerydin is an important addition to PharmaDerm’s product portfolio. This agreement provides us with an excellent growth opportunity and reinforces our leadership in the topical dermatology specialty market,” said Peter Goldschmidt, president of Sandoz. “Collaborations in key growth areas that offer potential for further synergies are an important part of our strategy of bringing high-quality, affordable medicines to patients.”